And in a secondary analysis of the TOPCAT trial, where TTR was calculated using linear interpolation in patients with heart failure with preserved ejection fraction, greater time in SBP target range was associated with decreased risk of cardiovascular outcomes and mortality events beyond BP (6). This evidence concerns the gene TTR and heart failure.